XEC Company Profile

Directing the concerns to the fourth quarter of 2022 earnings season the Major Pharmaceutical Preparations company lost money at $-0.42 per share, relative to the recent numbers of $-0.91 per share a year ago financial reporting period, In the previous financial reporting period the Cytomx Therapeutics Inc realized $-0.35 per share.

For the financial interval closing December 31 2022 Acer Therapeutics Inc increased a shortfall per share of $-0.54 per share compare to $-0.30 a year ago and advanced shortfall from $-0.31 per share from the previous financial reporting period.

Sales remained unscathed to $0.00 millions from $0.36 millions in the corresponding financial reporting period a year ago and sequentially Sales Tumbled from $0.00 millions.

A humbling fiscal period by PRET in the fiscal time-frame closing Dec 31 2022

For the most recent fiscal period PRET Losses have extended of $-7.81 per share compare to $-0.43 a year ago and earnings per share improved from $-14.52 per share from the preceding reporting period.

Sales depreciated by -5.307 % to $80.65 millions from $85.17 millions in the comparable reporting period a year ago and sequentially Sales advanced by 10.767 % from $72.81 millions.

For the most recent fiscal period Terns Pharmaceuticals Inc decreased a loss per share of $-0.23 per share compare to $-0.56 a year ago and EPS improved from $-0.44 per share from the previous reporting season.

Sales remained unscathed to $0.00 millions from $1.00 millions in the comparable reporting season a year ago and sequentially Sales advanced from $0.00 millions.

For the fourth quarter of 2022 company lost money of $-0.14 per share compare to $-0.14 a year before and from $0.00 per share from the previous quarter.

Sales remained unscathed by 0 % to $3.94 millions from $3.94 millions in the comparable quarter a year before and sequentially Sales advanced from $0.00 millions.